MedPageToday -- LOS ANGELES -- After further data review, the insulin-sensitizing agent rosiglitazone (Avandia) appears to have reduced rates of cardiovascular events in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial -- although, for the most part, the reductions did not reach statistical significance, researchers said here.
